Efﬁcacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women

Yi Chen†, Jun Zhu†, Yiqin Zhou†, Jinhui Peng* and Bo Wang*

Department of Orthopedics, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China

Denosumab, a human monoclonal antibody, acts against the receptor activator of nuclear factor-κB ligand and is a promising antiresorptive agent in patients with osteoporosis. This study aimed to update the efﬁcacy and safety of denosumab vs. placebo in osteoporosis or low bone mineral density (BMD) postmenopausal women. PubMed, Embase, Cochrane library, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) reporting the efﬁcacy and safety data of denosumab vs. placebo in osteoporosis or low BMD postmenopausal women. A random-effects model was used to calculate pooled weight mean differences (WMDs) or relative risks (RRs) with corresponding 95% conﬁdence intervals (CIs) for treatment effectiveness of denosumab vs. placebo.

Eleven RCTs including 12,013 postmenopausal women with osteoporosis or low BMD were preferred for the ﬁnal meta-analysis. The summary results indicated that the percentage change of BMD in the denosumab group was greater than that of BMD in placebo at 1/3 radius (WMD: 3.43; 95%CI: 3.24–3.62; p < 0.001), femoral neck (WMD: 3.05; 95%CI: 1.78–4.33; p < 0.001), lumbar spine (WMD: 6.25; 95%CI: 4.59–7.92; p < 0.001), total hip (WMD: 4.36; 95%CI: 4.07–4.66; p < 0.001), trochanter (WMD: 6.00; 95%CI: 5.95–6.05; p < 0.001), and total body (WMD: 3.20; 95%CI: 2.03–4.38; p < 0.001). Moreover, denosumab therapy signiﬁcantly reduced the risk of clinical fractures (RR: 0.57; 95%CI: 0.51–0.63; p < 0.001), nonvertebral fracture (RR: 0.83; 95%CI: 0.70–0.97; p = 0.018), vertebral fracture (RR: 0.32; 95%CI: 0.25–0.40; p < 0.001), and hip fracture (RR: 0.61; 95%CI: 0.37–0.98; p = 0.042). Finally, denosumab did not cause excess risks of adverse events. These ﬁndings suggested that postmenopausal women receiving denosumab had increased BMDs and reduced fractures at various sites without inducing any adverse events.

Keywords: denosumab, osteoporosis, bone mineral density, postmenopausal women, efﬁcacy, safety, meta-analysis

INTRODUCTION

Osteoporosis is deﬁned as a bone disease that is characterized by decreased bone mineral density (BMD) and deteriorated micro-architecture of the skeleton, causing fragile bones and fracture risk(Brown et al., 2006). Osteoporosis is common, with a prevalence of 20–40% in postmenopausal women and 6–8% in men ≥50years of age (DuBois et al., 2002; Sharma et al., 2008; Hernlund et al., 2013; Lee et al., 2013; Cosman et al., 2014; Institute for Clinical Systems Improvement (ICSI), 2017). It is more common in postmenopausal women, persons ≥65years of age, Caucasians, Asians, and
persons with a small body frame (Cosman et al., 2014; Institute for Clinical Systems Improvement (ICSI), 2017). Osteoporosis can occur as part of the aging process or secondarily due to nutritional deficiency, metabolic disorders, or medication side effects (National Library of Medicine, 2010; Cosman et al., 2014). Certain endocrine, gastrointestinal, hematologic, autoimmune, and central nervous system (CNS) disorders increase the risk of osteoporosis. Medications such as long-term anticoagulation (Caraballo et al., 1999; Gage et al., 2006), hormonal therapies (Tit et al., 2017; Tit et al., 2018), glucocorticosteroids (Eltimman et al., 2008; Loke et al., 2011), some immunosuppressants (Anastasilakis et al., 2019), lithium (Zamani et al., 2009), thiazolidinediones (glitazones) (Majumdar et al., 2016), selective serotonin reuptake inhibitors (Diem et al., 2007; Richards et al., 2007), and long-term proton pump inhibitor use (Ngamruengphong et al., 2011; Khalili et al., 2012) may also cause osteoporosis(Cosman et al., 2014; Institute for Clinical Systems Improvement (ICSI), 2017). Osteoporosis accounts for greater than 90% of hip and vertebral fractures in women aged 65–84 years (NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, 2001), utilizing major health services worldwide (Prevention and management of osteoporosis, 2003; Burge et al., 2007). With increase in the average life span, postmenopausal osteoporosis is becoming a serious public health issue in China and in many other countries. Moreover, osteoporotic fracture causes permanent disability, admission to institutional care, and even death (Sambrook and Cooper, 2006).

Currently, lifestyle recommendations (vitamin D and calcium supplementation, exercise, and smoking alcohol cessation) and antiresorptive agents as standard therapies for osteoporosis, with bisphosphonates as first-line treatment, were proved to have beneficial effects on BMD and risk of fragile fractures in postmenopausal women (Adachi et al., 2009; Clarke, 2009; Holick et al., 2011; Bauer, 2013; Cosman et al., 2014; Institute for Clinical Systems Improvement (ICSI), 2017; Qaseem et al., 2017). However, fracture occurs if the treatment strategies did not yield adequate response. Therefore, additional effective treatment agents should be identified to improve the prognosis of osteoporosis.

With advances in bone physiology, RANKL has already been identified as an important bone remodeling mediator. Moreover, RANK, as a receptor of RANKL, is observed during several stages of differentiation on osteoclast surface (Boyle et al., 2003; Hofbauer and Schoppet, 2004). The RANKL–RANK interaction is controlled by the soluble cytokine receptor, osteoprotegerin, which sequesters RANKL and neutralizes its effects (Simonet et al., 1997; Lacey et al., 1998).

Denosumab, a fully human monoclonal IgG2 antibody, binds to RANK ligand and affects the formation, function, and survival of osteoclasts (Fuller et al., 1998; Yasuda et al., 1998; Lacey et al., 2000). Several randomized controlled trials (RCTs) have been conducted for evaluating the treatment efficacy and safety of denosumab in osteoporosis or low-BMD postmenopausal women. But the treatment effectiveness of denosumab should be summarized to report the magnitude of effect estimates.

Therefore, this study aimed to investigate the treatment efficacy and safety of denosumab vs. placebo in osteoporotic or low-BMD postmenopausal women based on RCTs.

METHODS

Data Sources, Search Strategy, and Selection Criteria

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement guidelines were used to conduct this study (Moher et al., 2009). PubMed, Embase, Cochrane library, and ClinicalTrials.gov were explored for published articles from inception till May 2019. The following search terms were used to retrieve the articles: osteoporosis, postmenopause, postmenopausal, women, denosumab, and randomized controlled trials. To obtain more appropriate and highly accurate studies, the reference lists of the obtained articles were also reviewed.

Two researchers selected the articles after initial screening. After that, careful screening of titles and abstracts of these articles was done. If the study was considered relevant, then full text of the study was obtained. Eligible studies should meet the following inclusion criteria (Brown et al., 2006): study design: studies designed as RCTs (Hernlund et al., 2013); patients: osteoporotic or low-BMD postmenopausal women (Lee et al., 2013); intervention: denosumab (Dubois et al., 2002); control: placebo (Sharma et al., 2008); outcomes: BMD or fracture at various sites, and any other potential adverse events. If several publications were available with increasing number of patients or longer follow-up for the same group, only data of 1- to 3-year follow-up duration were used for statistical analysis.

Data Collection and Quality Assessment

The full-text and relevant data extraction from each study into the coding table in Microsoft Excel software was conducted by two reviewers. The following information including the first authors’ surname, publication year, country, sample size, mean age, body mass index (BMI), disease status, intervention and control, follow-up duration, and reported outcomes was extracted from each study. The JADAD scale was used to assess the quality of enrolled studies, which is based on randomization (1 or 0), concealment of the treatment allocation (1 or 0), blinding (1 or 0), completeness of follow-up (1 or 0), and the use of intention-to-treat analysis (1 or 0), and the scale system ranged from 0 to 5 (Jadad et al., 1996). The data collection and quality assessment were performed by two independent authors, and any conflicts between them were settled by an additional author by reviewing the original article.

Statistical Analysis

Effect estimates for continuous data were presented as weighted mean differences with its 95% confidence intervals (CIs), while those of categorical data were expressed as relative risks (RRs) with corresponding 95% CIs. If the data in individual studies were expressed as median and range, then the data were converted to estimated means ± standard deviation before analysis. The
summary effect estimates for efficacy and safety profiles were evaluated using the random-effects model (DerSimonian and Laird, 1986; Ades et al., 2005). Heterogeneity was evaluated across the included studies using I-square statistics and p value for Q statistics, and I-square greater than 50% or p < 0.10 was considered as significant heterogeneity (Higgins et al., 2003; Deeks et al., 2008). Sensitivity analysis was calculated to assess the impact of single individual trial from the overall analyses for clinical fractures (Pedroza-Tobias, 1999). Subgroup analyses for BMD and fractures were conducted based on the sites, and the treatment effects of denosumab among various sites were calculated using an interaction test (Altman and Bland, 2003). Publication bias for clinical fractures was evaluated using funnel plot (a pattern distribution roughly with the shape of a funnel indicates no publication bias), Egger (Egger et al., 1997), and Begg tests (Begg and Mazumdar, 1994). The inspective level for pooled results was 2-sided, and p < 0.05 was regarded as statistically significant. The analyses in this study were carried out through STATA software (version 12.0; Stata Corporation, College Station, TX, United States).

### TABLE 1 | Baseline characteristics of studies included in the meta-analysis.

| Study | Publication year | Country | Sample size | Mean age (years) | BMI (kg/m²) | Disease status | Intervention | Follow-up duration, months | JADAD scale |
|-------|------------------|---------|-------------|-----------------|-------------|----------------|--------------|---------------------------|------------|
| McClung (AMG 162) Sambrook and Cooper (2006) | 2006 United States | 360 | 63.3 | 26.8 | Lumbar spine BMD T score: 2.2; total hip BMD T score: 1.4; femoral neck BMD T score: 1.9; total body BMD T score: 1.4 | Denosumab (6 mg, 14 mg, and 30 mg for 3 months; 14 mg, 60 mg, 100 mg, and 210 mg for 6 months); placebo | 12.0 | 4 |
| Bone Adachi et al. (2009) | 2008 North America | 332 | 59.4 | 26.4 | Lumbar spine BMD T score: 1.61 | Denosumab 60 mg every 6 months for 2 years; placebo | 24.0 | 4 |
| Ellis Bauer (2013) | 2009 United States and Canada | 252 | 59.4 | 27.8 | Lumbar spine BMD T score: 1.06; total hip BMD T score: 0.95; femoral neck BMD T score: 1.27 | Denosumab 60 mg every 6 months for 1 year; placebo | 12.0 and 24.0 | 4 |
| Cummings (FREEDOM) Holick et al. (2011) | 2009 Multiple countries | 7,808 | 72.3 | 26.0 | Lumbar spine BMD T score: 2.83; total hip BMD T score: 1.90; femoral neck BMD T score: 2.16 | Denosumab 60 mg every 6 months for 3 years; placebo | 36.0 | 4 |
| Seeman Clarke (2009) | 2010 Argentina, Australia, Canada, France, and United States | 165 | 60.5 | NA | Lumbar spine BMD T score: 2.40; total hip BMD T score: 1.28 | Denosumab 60 mg every 6 months for 1 year; placebo | 12.0 | 5 |
| Bone Oaseem et al. (2017) | 2011 United States and Canada | 256 | 59.1 | 26.7 | Lumbar spine BMD T score: 1.61 | Denosumab 60 mg every 6 months for 2 years; placebo | 24.0 | 4 |
| Kumagai Boyle et al. (2003) | 2011 Japan | 40 | 57.6 | 22.3 | NA | Denosumab 60 mg every 6 months for 1 year; placebo | 9.0 | 3 |
| Nakamura Hofbauer and Schoppet (2004) | 2012 Japan | 212 | 65.1 | 22.3 | Lumbar spine BMD T score: 3.06; total hip BMD T score: 1.85 | Denosumab 60 mg every 6 months for 3 years; placebo | 12.0 | 4 |
| Nakamura (DIRECT) Simonet et al. (1997) | 2014 Japan | 905 | 69.4 | 22.5 | Lumbar spine BMD T score: 2.75; total hip BMD T score: 1.98; femoral neck BMD T score: 2.33 | Denosumab 60 mg every 6 months for 1 year; placebo | 36.0 | 4 |
| Grant (ABC1-18) Lacey et al. (1998) | 2015 Austria and Sweden | 1,548 | 64.0 | NA | Lumbar spine BMD T score: <-1.0 | Denosumab 60 mg every 6 months for 2 years; placebo | 24.0 | 5 |
| Koh Fuller et al. (1998) | 2016 Korea | 135 | 66.5 | 23.6 | Lumbar spine BMD T score: 2.96; total hip BMD T score: 1.95; femoral neck BMD T score: 2.45 | Denosumab 60 mg every 6 months for 1 year; placebo | 12.0 | 4 |

The JADAD scale was used to assess the quality of enrolled studies, which is based on randomization (1 or 0), concealment of the treatment allocation (1 or 0), blinding (1 or 0), completeness of follow-up (1 or 0), and the use of intention-to-treat analysis (1 or 0), and the scale system ranged from 0 to 5 (Jadad et al., 1996).
RESULTS

Literature Search
A preliminary initial search yielded 971 related records. After the titles and abstracts were reviewed, 918 studies were excluded due to duplications or irrelevant topics. For the remaining 53 articles, full texts were obtained and then reviewed. Of these, 42 were excluded for the following reasons: they used other control agents (n = 23), studies reported the same population (n = 16), and they were with no desirable outcomes (n = 3). Manual searching of the reference lists of the remaining studies yielded no additional study. Finally, 11 RCTs were selected for conducting this meta-analysis (Table 1; McClung et al., 2006; Bone et al., 2008; Ellis et al., 2008; Cummings et al., 2009; Seeman et al., 2010; Bone et al., 2011; Kumagai et al., 2011; Nakamura et al., 2012; Nakamura et al., 2014; Gnant et al., 2015; Koh et al., 2016). Figure 1 represents a flowchart of the selection process, and inclusion and exclusion criteria.

Study Characteristics
Eleven RCTs recruited a total of 12,013 osteoporotic or low-BMD postmenopausal women. The follow-up duration for participants ranged from 9 to 36 months, and 40–7,808 patients were included in each trial. The mean age of enrolled patients ranged from 57.6 to 72.3 years, and BMI ranged from 22.3 to 27.8 kg/m². Six studies were conducted in Western countries, four studies in Eastern countries, and the remaining one study in multiple countries. Two trials had a score of 5, eight trials had a score of 4, and the remaining one trial had a score of 3.

Bone Mineral Density
The summary results regarding the effectiveness of denosumab vs. placebo on BMD at various sites are presented in Figure 2. Overall, the results showed that the percentage of change in BMD was significantly increased with denosumab when compared with placebo at 1/3 radius (WMD: 3.43; 95% CI: 3.24 to 3.62; p < 0.001), femoral neck (WMD: 3.05; 95% CI: 1.78 to 4.33; p < 0.001), lumbar spine (WMD: 6.25; 95% CI: 4.59 to 7.92; p < 0.001), total hip (WMD: 4.36; 95% CI: 4.07 to 4.66; p < 0.001), trochanter (WMD: 6.00; 95% CI: 5.95 to 6.05; p < 0.001), and total body (WMD: 3.20; 95% CI: 2.03 to 4.38; p < 0.001). The included studies showed a significant heterogeneity for BMD at 1/3 radius, femoral neck, lumbar spine, total hip, and total body.

Fracture
The breakdown of the number of trials available for clinical fractures, nonvertebral fractures, vertebral fractures, and hip fractures was six trials, three trials, three trials, and one trial, respectively. The summary RRs indicated that the risk of clinical fractures (RR: 0.57; 95% CI: 0.51 to 0.63; p < 0.001), nonvertebral fractures (RR: 0.83; 95% CI: 0.70 to 0.97; p = 0.018), vertebral fractures (RR: 0.32; 95% CI: 0.25 to 0.40; p < 0.001), and hip fractures (RR: 0.61; 95% CI: 0.37 to 0.98; p = 0.042) was significantly reduced in patients who received denosumab (Figure 3). The included trials showed no heterogeneity for clinical fractures, nonvertebral fractures, and vertebral fractures. The results of sensitivity analysis indicated that the pooled conclusion for clinical fracture was stable and was unaltered by excluding any particular trial (Figure 4). Finally, no significant publication bias was detected through clinical fracture data (p value for Egger: 0.742; p value for Begg: 0.707; Figure 5).

Safety Profiles
The summary results regarding the risk of adverse events are summarized in Supplementary Table S1. First, no significant differences were observed between denosumab and placebo for the risk of any adverse events (RR: 1.00; 95% CI: 0.99–1.01; p = 0.995; without evidence of heterogeneity), treatment-related adverse events (RR: 0.96; 95% CI: 0.75–1.23; p = 0.740; without evidence of heterogeneity), withdrawal due to adverse events (RR: 1.12; 95% CI: 0.84–1.48; p = 0.435; without evidence of heterogeneity), and death (RR: 0.80; 95% CI: 0.59–1.07; p = 0.137; without evidence of heterogeneity). Second, for adverse events that occur in at least 10% of subjects, complications such as constipation (RR: 1.53; 95% CI: 1.01–2.32; p = 0.043), flatulence (RR: 1.58; 95% CI: 1.12–2.22; p = 0.008), pharyngolaryngeal pain (RR: 3.02; 95% CI: 1.12–8.11; p = 0.029), and rash (RR: 3.00; 95% CI: 1.17–7.68; p = 0.022) were significantly increased in patients who received denosumab, whereas denosumab therapy was associated with low risk of falling (RR: 0.80; 95% CI: 0.66–0.97; p = 0.022) and periarthritis (RR: 0.17; 95% CI: 0.04–0.66; p = 0.010). No other significant difference was detected for any specific adverse events. Finally, denosumab and placebo showed no significant differences regarding the occurrence of serious adverse events or specific serious adverse events.
DISCUSSION

The prevalence of osteoporosis is on the rise and has become a serious public health issue of global concern, especially in postmenopausal women with advanced age, inducing greater fracture risk at various sites. The current study was conducted based on 11 RCTs with 12,013 osteoporosis or low-BMD postmenopausal women to evaluate the efficacy and safety of denosumab vs. placebo across a wide range of characteristics. The results of this study suggested that denosumab showed association with high percentage change in BMD at 1/3 radius, femoral neck, lumbar spine, total body, trochanter, and total body. Moreover, the risk of various types of fractures such as clinical fractures, nonvertebral fractures, vertebral fractures, and hip fractures was significantly reduced in patients who received denosumab. Furthermore, denosumab did not yield additional risks on any adverse events, treatment-related adverse events, withdrawal due to adverse events, and deaths. Although denosumab and placebo treatments showed significant differences, these results might vary as fewer number of trials were included. As for homogeneity, the results from studies with greater weight were similar. Hence, even though the results from studies with lower weight were more variable, the overall results were still robust.

There are a large number of systematic reviews and meta-analyses conducted focusing on denosumab for treating postmenopausal women with osteoporosis or low BMD. Anastasilakis et al. (2009) conducted a meta-analysis of three RCTs and showed a significant decrease in the bone markers and increase of lumbar and hip BMD after treatment with denosumab, whereas no significant benefits were observed on the risk of fracture, and increased the infection risk. von Keyserlingk et al. (2011) conducted a meta-analysis based on four RCTs, and reported significant reduction in the risk of fracture without increasing adverse events in postmenopausal women who received denosumab. Zhou et al. (2014) carried out a meta-analysis of 11 RCTs and demonstrated a significant reduction in the risk of nonvertebral fractures and additionally yielded serious adverse events related to infection in osteoporotic or low-BMD postmenopausal women after treatment with denosumab. The meta-analysis conducted by Gu et al. (2015) was based on four RCTs, and the results revealed that the BMD...
FIGURE 3 | Summary results of fracture risk at various sites.

FIGURE 4 | Sensitivity analysis of clinical fractures.
was increased and the bone turnover markers were decreased in postmenopausal women after treatment with denosumab, whereas no significant risk for adverse events was observed. However, several RCTs have already been conducted regarding the topic, but should reevaluate the magnitude regarding the treatment effectiveness of denosumab vs. placebo in osteoporotic or low-BMD postmenopausal women. Therefore, the current quantitative meta-analysis was conducted to update the efficacy and safety of denosumab vs. placebo in postmenopausal women with osteoporosis or low BMD.

The summary results indicated that the percentage change of BMD in the denosumab group was greater than that of BMD in placebo at 1/3 radius, femoral neck, lumbar spine, total hip, trochanter, and total body, and these results were consistent with previous meta-analyses (Anastasilakis et al., 2009; Gu et al., 2015). Moreover, these results from individual trials reported similar conclusions, and the results of this study provided the magnitude of pooled results. Moreover, the current study suggested that the risk of clinical fractures, nonvertebral fractures, vertebral fractures, and hip fractures was significantly reduced in patients who received denosumab. The potential reasons for these conclusions could be due to denosumab action in inhibiting RANKL, preventing bone resorption, increasing BMD, and reducing fracture risk in osteoporosis or low-BMD postmenopausal women (Bekker et al., 2004; Lewiecki et al., 2007).

The summary results showed that denosumab therapy caused greater risk of constipation, flatulence, pharyngolaryngeal pain, and rash, whereas the risk of falling and periartthritis were significantly reduced. The potential reasons for this could be that denosumab could affect the immune system of the patients taking it and is associated with these adverse events (Canalis, 2010; Moen and Keam, 2011). Moreover, the risk of falling and periartthritis were reduced due to increased levels of BMD in osteoporotic or low-BMD postmenopausal women (Hita-Contreras et al., 2014; Burnett et al., 2017).

Although the current study provides comprehensive effectiveness results regarding denosumab in osteoporotic or low-BMD postmenopausal women, several limitations still existed and should be mentioned. First, the summary results for BMD at various sites were available only in few trials, inducing instability in the magnitude of BMD in the denosumab group. Second, the risk of most of the adverse events was available in smaller trials, and the power might not be enough to detect the difference between denosumab and placebo groups. Finally, publication bias remained inevitable since the analysis was conducted on published RCTs and that the bias against the publication of negative results is well known (Murad et al., 2018).

In conclusion, the findings of this meta-analysis indicated that osteoporotic or low-BMD women who received denosumab had increased BMD and reduced fracture risk at various sites. Moreover, the frequency of adverse events between denosumab and placebo groups was similar. Future large-scale RCTs that compare the treatment effectiveness of denosumab with other traditional drugs in patients at various stages should be conducted.

AUTHOR CONTRIBUTIONS

YC carried out the studies, JZ and YZ participated in collecting data, and YC drafted the manuscript. JP and BW performed the statistical analysis and participated in its design. JZ and YZ helped to draft the manuscript. All authors read and approved the final manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.588095/full#supplementary-material.
Bauer, D. C. (2013). Clinical practice. Calcium supplements and fracture prevention. N. Engl. J. Med. 369 (16), 1537–1543. doi:10.1056/NEJMcp1210380
Begg, C. B., and Mazumdar, M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (4), 1088–1101. doi:10.2307/2533446
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., et al. (2004). A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner Res. 19 (7), 1059–1066. doi:10.1359/JBMR.040305
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y. C., et al. (2011). Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96 (4), 972–980. doi:10.1210/jc.2010-1502
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., et al. (2008). Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93 (6), 2149–2157. doi:10.1210/jc.2007-2814
Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003). Osteoclast differentiation and activation. Nature 429 (6997), 337–342. doi:10.1038/nature02658
Brown, J. P., Fortier, M., Frame, H., Lalonde, A., Papaianniou, A., Senikas, V., et al. (2006). Canadian Consensus Conference on osteoporosis, 2006 update. J. Obstet. Gynaecol. Can. 28 (2 Suppl 1), S95–S112. doi:10.1171/j.1701-2357.2006.00874X
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., and Tosteson, A. (2007). Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner Res. 22 (3), 465–475. doi:10.1359/bmr.061113
Burnett, W. D., Kontulainen, S. A., McLennan, C. E., Hazel, D., Talmo, C., Wilson, D. R., et al. (2017). Proximal tibial trabecular bone mineral density is related to pain in patients with osteoarthritis. Arthritis Res. Ther. 19 (1), 200. doi:10.1186/s13075-017-1415-9
Canalis, E. (2010). New treatment modalities in osteoporosis. J. Bone Miner Res. 25 (10), 2359–2380. doi:10.1002/jbmr.315. doi:10.1039/jbmr.2010.00005
Caraballo, P. J., Heit, J. A., Atkinson, E. J., Silverstein, M. D., O’Fallon, W. M., Castro, M. R., et al. (1999). Long-term use of oral anticoagulants and the risk of osteoporosis. The横线研究. Clin. Epidemiol. 448. doi:10.1016/S0002-9440(10)64556-7
Chan, A. T. (2012). Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 344, e372. doi:10.1136/bmj.e372
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chan, A. T. (2012). Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 344, e372. doi:10.1136/bmj.e372
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women
Chen et al. Analyzing Denosumab in Postmenopausal Women

Loke, Y. K., Cavallazzi, R., and Singh, S. (2011). Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. *Thorax* 66 (8), 699–708. doi:10.1136/thx.2011.160028

Majumdar, S. R., Josse, R. G., Lin, M., and Ehrich, D. T. (2016). Does sitaglipitin affect the rate of osteoporotic fractures in type 2 diabetes? Population-based cohort study. *J. Clin. Endocrinol. Metab.* 101 (5), 1963–1969. doi:10.1210/jc.2015-4180

National Library of Medicine (2010). Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. *Menopause* 17 (1), 25–54. doi:10.1097/gme.0b013e3181e61766

McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffet, A. H., et al. (2006). Denosumab in postmenopausal women with low bone mineral density. *New Engl. J. Med.* 354 (8), 821–831. doi:10.1056/NEJMoa044459

Moen, M. D., and Keam, S. J. (2011). Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. *Drugs Aging* 28 (1), 63–82. doi:10.2165/11203300-000000000-00000

Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 6 (7), e1000097. doi:10.1371/journal.pmed.1000097

Murray, M. H., Chu, H., Lin, L., and Wang, Z. (2018). The effect of publication bias magnitude and direction on the certainty in evidence. *BMJ Evid. Based Med.* 23 (3), 84–86. doi:10.1136/bmjebm-2018-110891

Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., et al. (2014). Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). *J. Clin. Endocrinol. Metab.* 99 (7), 2599–2607. doi:10.1210/jc.2013-4175

Nakamura, T., Matsumoto, T., Sugimoto, T., and Shiraki, M. (2012). Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. *Osteoporos.* Int. 23 (3), 1131–1140. doi:10.1007/s00198-011-1786-8

Ngamruengphong, S., Leontiadis, G. I., Radhi, S., Dentino, A., and Nugent, K. (2011). Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. *Am. J. Gastroenterol.* 106 (7), 1209–1219. doi:10.1038/ajg.2011.113

NIH Consensus Development Panel (2001). Osteoporosis prevention, diagnosis, and therapy. *Jama* 285 (6), 785–795. doi:10.1001/jama.285.6.785

Pedroza-Tobias, A. (1999). Assessing the influence of a single study in meta-analysis. *Stat. Tech. Bull.* 47, 15–17.

Prevention and management of osteoporosis (2003). World Health Organization technical report series. Report No.: 921, Vol. 921, 1–164. Available at: https://apps.who.int/iris/handle/10665/42841

Qaseem, A., Forciea, M. A., McLean, R. M., and Denberg, T. D. (2017). Clinical guidelines committee of the American College of P. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of physicians. *Ann. Intern. Med.* 166 (11), 818–839. doi:10.7326/M15-1361

Richards, J. B., Papaioannou, A., Adachi, J. D., Joseph, L., Whitson, H. E., Prior, J. C., et al. (2007). Effect of selective serotonin reuptake inhibitors on the risk of fracture. *Arch. Intern. Med.* 167 (2), 188–194. doi:10.1001/archinte.167.2.188

Sambrook, P., and Cooper, C. (2006). Osteoporosis. *Osteoporos. Lancet (London, England)* 367 (9527), 2010–2018. doi:10.1016/s0140-6736(06)68891-0

Seeman, E., Delmas, P. D., Hanley, D. A., Sellmeyer, D., Cheung, A. M., Shane, E., et al. (2010). Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. *J. Bone Miner Res.* 25 (8), 1868–1894. doi:10.1002/jbmr.81

Sharma, S., Fraser, M., Lovell, R., Reece, A., and McLellan, A. R. (2008). Characteristics of males over 50 years who present with a fracture: epidemiology and underlying risk factors. *J. Bone Jt. Surg Br* 90 (1), 72–77. doi:10.1302/0301-620X.90B1.18773

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., et al. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell* 89 (2), 309–319. doi:10.1016/s0092-8674(00)80209-3

Tit, D. M., Bungau, S., Iovan, C., Nistor Csepplento, D. C., Endres, L., Sava, C., et al. (2018). Effects of the hormone replacement therapy and of soy isoflavones on bone resorption in postmenopausal. *J. Clin. Med.* 7 (10), 297. doi:10.3390/jcm7100297

Tit, D. M., Pallag, A., Iovan, C., Furau, G., Furau, C., and Bungau, S. (2017). Somatic-vegetative symptoms evolution in postmenopausal women treated with phytoestrogens and hormone replacement therapy. *Iran J. Public Health* 46 (11), 1528–1534.

von Keyserlingk, C., Hopkins, R., Anastasilakis, A., Touulis, K., Goeree, R., Tarride, J. E., et al. (2011). Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. *Semin. Arthritis Rheum.* 41 (2), 178–186. doi:10.1016/j.semarthrit.2011.03.005

Vyasu, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., et al. (1997). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc. Natl. Acad. Sci. U.S.A.* 95 (7), 3597–3602. doi:10.1073/pnas.95.7.3597

Zamani, A., Omrani, G. R., and Nasab, M. M. (2009). Lithium’s effect on bone mineral density. *Bone* 44 (2), 331–334. doi:10.1016/j.bone.2008.10.001

Zhou, Z., Chen, C., Zhang, J., Ji, X., Liu, L., Zhang, G., et al. (2014). Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. *Int. J. Clin. Exp. Pathol.* 7 (5), 2113–2122.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Chen, Zhu, Zhou, Peng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.